Vascular Endothelial Growth Factor in Colonic Cancer, Ulcerative Colitis and Colonic Adenoma: An Immunohistochemical Study

Amina A. Gamal el Din; Reham Sh. E. Esmail; Amal A. Hareedy

doi:10.3889/oamjms.2014.075

Authors

Amina A. Gamal el Din National Research Center, Pathology, Cairo
Reham Sh. E. Esmail National Research Center, Pathology, Cairo
Amal A. Hareedy Cairo University, Pathology, Cairo

DOI:

https://doi.org/10.3889/oamjms.2014.075

Keywords:

VEGF, ulcerative colitis, colon cancer, colonic adenoma

Abstract

BACKGROUND: Colon cancer is one of the most common malignancies worldwide. Colonic adenoma and ulcerative colitis (UC) are important precancerous lesions. Vascular Endothelial Growth Factor (VEGF) is a well-known pro-angiogenic factor plays important role in physiologic and pathologic conditions and in neovascularization in cancer and hence becomes a potential target for anti-angiogenic cancer therapy.

AIM: This study investigated VEGF immunohistochemical expression in colon cancer and its precancerous lesions.

MATERIAL AND METHODS:Â Paraffin blocks from two hospitals were collected in a year: Colon cancer: 20 cases, colonic adenoma: 15 cases, UC: 15 cases and 5 controls from normal mucosa. VEGF was assessed immunohistochemically using a primary anti-VEGF antibody (VG1, Dako, Denemark).

RESULTS: Median age was 49 years (range 31-52) in cancer, 40 years (range 31-52) in adenomas and 33 years (range 27-43) in UC. VEGF expression was negative in control, significantly strongly positive in 90% of colonic adenocarcinoma (p= 0.001), significantly positive in adenomas (p= 0.002) - the weak positivity significantly seen in mild dysplasia (p= 0.001) - and significantly positive in 73.3% of UC cases (p=0.022).

CONCLUSION: The significant increase in positivity of VEGF in precancerous to cancerous lesions may point to its potential role in the pathogenesis and progression of colonic neoplasia.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Veruttipong D, Soliman AS, Gilbert SF, Blachley TS, Hablas A, Ramadan M, Rozek LS, Seifeldin IA. Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. World J Gastroenterol. 2012; 18(30): 3997-4003. DOI: https://doi.org/10.3748/wjg.v18.i30.3997

Mokhtar N, Gouda I, Adel I (editors). Malignant endocrine system tumors. In : Cancer pathology registry 2003-2004 and time trend analysis 1ST edition. NCI, 2007: 91-93.

Zhang Y, Liu X, Zhang J, Li L, and Liu C. The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer. Oncol Lett. 2012; 4: 763â€“766. DOI: https://doi.org/10.3892/ol.2012.822

Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191-7. DOI: https://doi.org/10.1055/s-0029-1242458

Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, Chen K, Hamilton SR, Fan D, Sun B, Zhang W. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res. 2011;17:4331-40. DOI: https://doi.org/10.1158/1078-0432.CCR-11-0226

Berger AW, Ettrich TJ, Dollinger MM. Colon Polypectomy - And Then? .Zentralbl Chir. 2013. [Epub ahead of print]

Nussrat FL, Ali HH,Hussein HG,AL-Ukashi RJ. Immunohistochemical Expression of ki-67 and p53 in Colorectal Adenomas: A Clinicopathological Study. Oman Med J 2011; 26:229-234. DOI: https://doi.org/10.5001/omj.2011.57

Tocantins de Sousa WA, Rodrigues LV, Silva Jr RG, Vieira FL. Immunohistochemical evaluation of p53 and Ki-67 proteins in colorectal adenomas. Arq Gastroenterol. 2012;49:35-40. DOI: https://doi.org/10.1590/S0004-28032012000100007

Rogler G. Inflammatory bowel disease cancer risk, detection and surveillance. Dig Dis. 2012;30:48-54. DOI: https://doi.org/10.1159/000341893

Lukas M. Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis. 2010;28:619-24. DOI: https://doi.org/10.1159/000320276

Lichtenstein GR& Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-46. DOI: https://doi.org/10.1002/ibd.20997

Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-45. DOI: https://doi.org/10.1016/j.cgh.2012.01.010

Raica M, Cimpean AM, Ribatti D. Angiogenesis in pre-malignant conditions. Eur J Cancer. 2009;45:1924-34. DOI: https://doi.org/10.1016/j.ejca.2009.04.007

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W, Reinacher-Schick A. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol. 2011 ;49:1398-406. DOI: https://doi.org/10.1055/s-0031-1281752

Pringels S, Van Damme N, De Craene B, Pattyn P, Ceelen W, Peeters M, Grooten J. Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members. BMC Cancer. 2012; 12: 515. DOI: https://doi.org/10.1186/1471-2407-12-515

Liang J, Wang H, Xiao H, Li N, Cheng C, Zhao Y, Ma Y, Gao J, Bai R Zhen H. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res. 2010, 29:71. DOI: https://doi.org/10.1186/1756-9966-29-71

Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17â€“24. DOI: https://doi.org/10.1200/JCO.2010.30.1077

LazÄƒr D, Raica M, Sporea I, TÄƒban S, GoldiÅŸ A, Cornianu M. Tumor angiogenesis in gastric cancer. Rom J Morphol Embryol. 2006;47(1):5-13.

Islam R, Chyou PH, Burmester JK. Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer. 2013 Apr 29;4(4):330-5. DOI: https://doi.org/10.7150/jca.6083

Chen JC, Chang YW, Hong CC, Yu YH and Su JL. Review The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy. Int J Mol Sci. 2013; 14, 88-107. DOI: https://doi.org/10.3390/ijms14010088

Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432. DOI: https://doi.org/10.1186/1471-2407-9-432

Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56(3):209-13. DOI: https://doi.org/10.1136/jcp.56.3.209

Kapsoritakis A, Sfiridaki A, Maltezos E, Simopoulos K, Giatromanolaki A, Sivridis E, Koukourakis MI. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18(5):418-22. DOI: https://doi.org/10.1007/s00384-003-0495-y

Alkim C, Sakiz D, Alkim H, Livaoglu A, Kendir T, Demirsoy H, Erdem L, Akbayir N, Sokmen M. Thrombospondin-1 and VEGF in inflammatory bowel disease. Libyan J Med. 2012;7. DOI: https://doi.org/10.3402/ljm.v7i0.8942

Griga T, May B, Pfisterer O, MÃ¼ller KM, Brasch F. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 2002;49(43):116-23.

Tsiolakidou G, Koutroubakis IE, Tzardi M, Kouroumalis EA. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. Dig Liver Dis. 2008;40(8): 673-679. DOI: https://doi.org/10.1016/j.dld.2008.02.010

Tolstanova G, Khomenko T, Deng X, Szabo S, Sandor Z. New molecular mechanisms of the unexpectedly complex role of VEGF in ulcerative colitis. Biochem Biophys Res Commun. 2010;399(4):613-6. DOI: https://doi.org/10.1016/j.bbrc.2010.07.124

Tolstanova G, Khomenko T, Deng X, Chen L, Tarnawski A, Ahluwalia A, Szabo S, Sandor Z. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther. 2009;328(3):749-57. DOI: https://doi.org/10.1124/jpet.108.145128

Pousa ID, MatÃ© J, Salcedo-Mora X, Abreu MT, Moreno-Otero R, Gisbert JP. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis. 2008;14(1):61-7. DOI: https://doi.org/10.1002/ibd.20269